Tarsus Pharmaceuticals, Inc.
TARS
$59.10
-$0.73-1.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 16.79% | 33.47% | 38.13% | 19.03% | -8.68% |
| Total Depreciation and Amortization | -1.35% | -3.70% | 1.55% | -1.52% | 6.48% |
| Total Amortization of Deferred Charges | 1.92% | 2.63% | 4.11% | 5.04% | 0.72% |
| Total Other Non-Cash Items | -17.25% | 24.10% | 62.50% | 16.07% | -5.06% |
| Change in Net Operating Assets | -317.13% | -29.77% | 218.18% | -756.28% | 66.65% |
| Cash from Operations | -227.53% | 5.88% | 162.13% | -42.30% | 6.90% |
| Capital Expenditure | 8.49% | -232.88% | -90.81% | -69.66% | -719.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -194.81% | 2,063.71% | 94.41% | -47.60% | 42.27% |
| Cash from Investing | -218.85% | 1,138.88% | 90.83% | -47.97% | 41.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.92% | -9.76% | 31.25% | -98.57% | 4,565.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.92% | -9.76% | 31.25% | -98.57% | 4,565.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -215.64% | 341.13% | 120.31% | -197.74% | 202.71% |